Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial
Pharmacology, Toxicology and Pharmaceutical Science
3
2%
Neuroscience
3
2%
Environmental Science
2
2%
Other
6
5%
Unknown
68
54%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 58. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 July 2026.
All research outputs
#939,558
of 34,492,055 outputs
Outputs from The Lancet Haematology
#179
of 1,590 outputs
Outputs of similar age
#19,650
of 569,647 outputs
Outputs of similar age from The Lancet Haematology
#5
of 49 outputs
Altmetric has tracked 34,492,055 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,590 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 29.6. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 569,647 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.
